Kuros Biosciences’ released its MagnetOS minimally invasive spine delivery system in a full commercial launch.
MagnetOS is a bone graft delivery system and is sterile, prefilled, free of human tissue and has a mechanism of action backed by Level I clinical evidence.
“The launch of MagnetOs MIS is more than a product milestone – it reflects our vision to redefine what’s possible in spine surgery,” Chris Fair, CEO of Kuros, said in a Sept. 30 news release. “By combining efficiency, precision, and the strength of Level I clinical evidence, we’re setting a new standard for minimally invasive care. At Kuros, our mission is to empower surgeons with innovations that don’t just keep pace with the future of surgery but help shape it.”
